EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy

By sjmartinez • October 30, 2022

Kang JJ, Ko A, Kil SH, Clair JM, Shin DS, Wang MB, Srivatsan ES. EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. Biochim Biophys Acta Rev Cancer. 2022 Oct 26:188827. doi: 10.1016/j.bbcan.2022.188827. Epub ahead of print. PMID: 36309124.

Tags: Epidermal growth factor receptor, Head and neck cancer, Head and neck squamous cell carcinoma, Hematology/Oncology, immunotherapy, Monoclonal antibodies, Publications, Receptor tyrosine kinase, Small molecular inhibitors, Veterans Administration

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, Mukohara T, Lisberg A, Shimizu T, Spira AI, Tsurutani J, Damodaran S, Papadopoulos[...]

Psychoneuroimmunology in multiple myeloma and autologous hematopoietic stem cell transplant: Opportunities for research among patients and caregivers

Christian LM, Kiecolt-Glaser JK, Cole SW, Burd CE, Madison AA, Wilson SJ, Rosko AE. Psychoneuroimmunology in multiple myeloma and autologous hematopoietic stem cell transplant: Opportunities[...]

Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial

Soto-Perez-de-Celis E, Dale W, Katheria V, Kim H, Fakih M, Chung VM, Lim D, Mortimer J, Cabrera Chien L, Charles K, Roberts E, Vazquez J,[...]